Cardiology

Top Story

CANTOS: Canakinumab reduces risk for major CV events in patients with MI, inflammatory atherosclerosis

June 22, 2017

In patients with prior MI and inflammatory atherosclerosis, canakinumab in combination with standard-of-care therapy reduced risk for major adverse CV events, according to the topline results of the CANTOS study announced by Novartis.

According to a press release from Novartis, the phase III study of canakinumab, also known as ACZ885, met its primary endpoint of reduction in major adverse CV events, defined as CV death, nonfatal MI and nonfatal stroke. Median follow-up for the 10,061 patients in the study was 3.8 years.

In the Journals

Off-label TAVR procedures common

June 22, 2017
Although in-hospital and 30-day mortality is greater among the nearly 1 in 10 patients in the United States who receive transcatheter aortic valve replacement for…
In the Journals

Head position may not affect outcomes during acute stroke treatment

June 22, 2017
During treatment for acute stroke, whether a patient was lying down or sitting up did not make a difference in disability outcomes, according to a study in The New
In the Journals

Statins may increase risk for Parkinson’s disease

June 21, 2017
Use of statins was significantly associated with risk of developing Parkinson’s disease, suggesting statins should not be used to protect against the disease as…
In the Journals

Breast-feeding may lower risk for CVD, stroke

June 21, 2017
Women who breast-fed had a lower risk for CVD and stroke compared with women who never breast-fed, according to a study published in the Journal of the American Heart
More News Headlines »
Advertisement
Advertisement